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        Introduction 
  Adult epidermis is a stratifi  ed epithelium in which keratinocytes 
from the basal and suprabasal layers cease to divide concomi-
tantly with their outward movement and terminal differentiation 
all through enucleation and keratinization. After injury, the 
  restoration of its functional integrity is of utmost importance to 
the survival of the organism. The maintenance of epithelium 
and its regeneration to close the wound is orchestrated with 
the contribution of the underlying dermal tissue. This syn-
chrony is key to preventing either insuffi  cient or excess wound 
repair. The regulation of wound repair is dictated by epithelial  –
  mesenchymal interactions and purportedly mediated by the 
  action of central players such as growth factors. This complex 
interplay demands the expression of soluble factors exerting 
autocrine and paracrine activities and, importantly, the integra-
tion of such diverse signals, which culminate in appropriate 
cellular responses (  Fusenig, 1994  ). Although the importance of 
the epithelial  –  mesenchymal communication is well recognized, 
the mechanism underlying this process needs in-depth study. 
  Of the numerous cytokines produced by skin cells, 
interleukin-1 (IL-1) has a pronounced infl  uence on skin homeo-
stasis and wound repair, and there are multiple mechanisms to 
regulate IL-1 signaling (  Schroder, 1995  ). Both human and mouse 
keratinocytes constitutively produce biologically active IL-1   /   
( Arend et al., 1998 ). The two distinct forms of IL-1, termed IL-1   
and IL-1    , are capable of binding to the same receptor with similar 
affi  nities to trigger biological effects. For any cells to respond 
productively to IL-1   /   , they must possess corresponding cell 
surface receptors. Two distinct IL-1 receptors (IL-1Rs) have been 
cloned and characterized. The type I IL-1R (IL-1R1) mediates all 
S
kin morphogenesis, maintenance, and healing after 
wounding require complex epithelial  –  mesenchymal 
interactions. In this study, we show that for skin 
homeostasis, interleukin-1 (IL-1) produced by keratino-
cytes activates peroxisome proliferator  –  activated recep-
tor     /     (PPAR    /    ) expression in underlying ﬁ  broblasts, 
which in turn inhibits the mitotic activity of keratinocytes 
via inhibition of the IL-1 signaling pathway. In fact, 
PPAR    /     stimulates production of the secreted IL-1 re-
ceptor antagonist, which leads to an autocrine decrease 
in IL-1 signaling pathways and consequently decreases 
production of secreted mitogenic factors by the ﬁ  bro-
blasts. This ﬁ  broblast PPAR    /     regulation of the IL-1 sig-
naling is required for proper wound healing and can 
regulate tumor as well as normal human keratinocyte 
cell proliferation. Together, these ﬁ  ndings  provide  evi-
dence for a novel homeostatic control of keratinocyte 
proliferation and differentiation mediated via PPAR    /     
regulation in dermal ﬁ  broblasts of IL-1 signaling. Given 
the ubiquitous expression of PPAR    /    , other epithelial  –
  mesenchymal interactions may also be regulated in a 
similar manner.
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  Results 
  PPAR    /     knockdown in dermal ﬁ  broblasts 
results in increased keratinocyte 
proliferation 
  Earlier studies have shown that ligand-activated PPAR   /   
induced the differentiation of human keratinocytes in mono-
layer cultures (  Tan et al., 2001  ;   Schmuth et al., 2004  ). Herein, 
we examined the autocrine and paracrine consequences of 
PPAR   /    defi  ciency during human epidermis formation using 
the organotypic skin culture (OTC) model. We fi  rst examined 
the expression pattern of the three PPAR isotypes in fi  broblasts 
and keratinocytes of control OTC. Both quantitative real-time 
PCR (qPCR) and ELISA analyses performed on mechanically 
separated dermis and epidermis equivalents of OTCs revealed 
that PPAR   /    is the predominant isotype in the keratinocytes 
and dermal fi  broblasts, whereas the lower levels of PPAR    
and PPAR     are comparable (  Fig. 1 A  ). We next assessed the 
knockdown effi  ciency of PPAR   /    expression in human kera-
tinocytes and fi  broblasts by lentivirus-mediated siRNAs using 
qPCR and immunoblot analyses. qPCR revealed a   >  95% reduc-
tion of PPAR   /    expression in cells transduced with the siRNA 
PPAR   /   11 sequence (  Fig. 1 B  , left). Immunoblot analysis 
also showed negligible levels of PPAR   /    protein in the trans-
duced cells (  Fig. 1 B  , right). These cells were used for subse-
quent experiments. 
  Next, OTCs were reconstructed using control keratino-
cytes (K    CTRL   ),  PPAR  /    knockdown  keratinocytes  (K   PPAR   /     ), 
control fi  broblasts (F    CTRL    ), and PPAR   /    knockdown fi  broblasts 
(F    PPAR   /      ) in various combinations. Immunoblot analysis and 
immunofl  uorescence staining of the 2-wk-old K   CTRL   /F   CTRL    OTCs 
showed the expected keratinocyte differentiation markers kera-
tin 5, keratin 10, and involucrin (  Fig. 1 C   and   Fig. S1  ). OTCs 
with K    PPAR   /       showed a reduced expression of terminal markers, 
which is consistent with the known prodifferentiation role of 
PPAR   /    (  Fig. 1 C   and Fig. S1;   Schmuth et al., 2004  ). No dif-
ference in keratin 5 expression, localized to the basal layer of 
the epidermis, was observed among the various OTCs (  Fig. 1 C   
and Fig. S1). This provided evidence for a cell-autonomous 
action of PPAR   /    in keratinocyte differentiation. Interestingly, 
OTC with F    PPAR   /       led to increased keratinocyte proliferation 
as indicated by an increase in expression of cyclin D1 and pro-
liferating cell nuclear antigen (PCNA;   Fig. 1 C  ) and in Ki67-
positive cells with respect to the control OTC (Fig. S1). Notably, the 
K    PPAR   /     /F   PPAR   /      OTC similarly displayed this enhanced prolifer-
ation of keratinocytes regardless of the impaired differentiation 
of the K    PPAR   /       (  Fig. 1 C   and Fig. S1). Furthermore, OTC with 
K    PPAR   /       showed threefold more apoptotic cells (TUNEL posi-
tive) and a higher level of cleaved caspase 3 as compared with 
OTC with K    CTRL     (  Fig. 1 C   and Fig. S1). A dynamic epithelial  –
  mesenchymal interaction is essential for the proper formation 
of the basement membrane (  Smola et al., 1998  ). The reduced 
laminin 5 staining in OTCs with either K    PPAR   /       or  F   PPAR   /       sug-
gested a dysregulated epithelial  –  mesenchymal communication 
(Fig. S1). Altogether, these results are consistent with the obser-
vations from KO mice (  Peters et al., 2000  ;   Michalik et al., 2001  ) 
and revealed a potent proliferation stimulatory effect of F    PPAR   /      
known responses of IL-1. In contrast, the type 2 IL-1R (IL-1R2) 
is incapable of participating in signal transduction by virtue of its 
short cytoplasmic tail and thus is thought to neutralize the action 
of the bound IL-1   /   . Interestingly, the predominant IL-1R 
  species expressed by keratinocytes, both constitutively and after 
activation of the cells, is the IL-1R2. Its production by keratino-
cytes would represent an effi  cient mean for these cells to escape 
autocrine IL-1   /    signaling (  Rauschmayr et al., 1997  ). In con-
trast, the dermal fi  broblasts express mainly the IL-1R1 isotype 
and thus are very sensitive to IL-1   /    signaling. 
  The effects of IL-1   /    on target cells can also be inhibited 
via the binding of the IL-1R antagonist (IL-1ra) to IL-1R1. 
There are two structural variants of IL-1ra, secreted IL-1ra 
(sIL-1ra) and intracellular IL-1ra (icIL-1ra). Both isoforms are 
transcribed from the same gene via two different promoters and 
alternative fi  rst exons. IL-1ra binds to IL-1R1 with an affi  nity 
that is 100  –  500 times higher than for IL-1R2 and competitively 
inhibits IL-1   /    binding to the receptor. Although icIL-ra may 
be released from keratinocytes under some conditions to com-
pete for receptor binding, it can inhibit IL-1   /   – induced  cytokine 
production intracellularly via the COP9 signalosome (  Banda 
et al., 2005  ). Fibroblasts produce both IL-1ra isoforms when 
appropriately stimulated, whereas keratinocytes only constitu-
tively produce the icIL-1ra (  Arend et al., 1998  ). 
  Peroxisome proliferator  –  activated receptors (PPARs) are 
nuclear hormone receptors involved in the control of chronic 
diseases such as diabetes and obesity (  Kersten et al., 2000  ). 
The PPAR subgroup comprises three related members named 
PPAR     (NR1C1),  PPAR  /    (NR1C2), and PPAR     (NR1C3; 
  Nuclear Receptors Nomenclature Committee, 1999  ). Ligand-
activated PPARs form obligate heterodimers with the retinoid X 
receptor and bind to defi  ned peroxisome proliferator response 
elements (PPREs) in the regulatory regions of target genes. 
Several works have shown that ligand-activated PPAR   /    can 
induce terminal differentiation of keratinocytes (  Tan et al., 2001  ; 
  Burdick et al., 2006  ). Other studies comparing PPAR   /  -null 
(KO) with wild-type (WT) mice showed that infl  ammatory sig-
nals increase the expression and activity of PPAR   /  ,  which 
confer a pronounced antiapoptotic capacity to the keratinocytes, 
mediated in part via the increased activity of the PKB     survival 
pathway (  Tan et al., 2001  ;   Di Poi et al., 2002  ). Nonetheless, it is 
paradoxical that in the KO mice, epidermal hyperproliferation 
was observed either in early wound repair, upon hair plucking, 
or in response to a topical challenge with the phorbol ester (TPA; 
  Peters et al., 2000  ;   Michalik et al., 2001  ). Thus, the role of 
PPAR   /    on cell proliferation remains debatable, and its mech-
anism of action is not suffi  ciently known (  Michalik et al., 2001  ; 
  Kim et al., 2005  ;   Man et al., 2008  ). 
  Herein, we provide evidence for a novel paracrine effect 
of PPAR   /    on epithelial cell growth. We found that PPAR   /   
in the fi  broblasts attenuates keratinocyte proliferation by directly 
increasing the expression of sIL-1ra, thereby repressing IL-1 
signaling. Epithelial  –  mesenchymal communications and IL-1 
signaling are responsible for a wide range of biological events 
such as wound repair and tumorigenesis. Our results underscore 
the paracrine role of PPAR   /    in the control of cell proliferation 
involving epithelial  –  mesenchymal interactions. 819 PARACRINE ACTION OF PPAR    /     IN EPIDERMIS   • Chong et al. 
  Figure 1.       PPAR    /    -deﬁ  cient ﬁ  broblasts increase epidermal proliferation.   (A) Expression proﬁ  le of PPARs in OTC keratinocytes and ﬁ  broblasts. Total RNA 
and protein were extracted from keratinocytes and ﬁ  broblasts in OTC. Expression levels of PPAR mRNA (left) and protein (right) were monitored by qPCR 
and PPAR transcription factor assay kit, respectively. PPAR    /     mRNA was normalized with control ribosomal protein P0 mRNA. (B) Human keratinocytes 
or ﬁ  broblasts were transduced with a lentiviral vector harboring a control or two different PPAR    /     (PPAR    /    9 and PPAR    /    11) siRNAs. (C) Immunoblot 
analysis of epidermis from 2-wk-old OTCs constructed using K    CTRL     or K    PPAR    /        and F    CTRL     or F    PPAR    /       . Involucrin and transglutaminase I (Tgase I) are terminal 
differentiation markers, and keratin 10 (CK10) is an early differentiation marker. Keratin 5 (CK5) identiﬁ  es the basal keratinocytes. Cell proliferation was 
measured using PCNA and cyclin D1. Apoptosis was detected using caspase 3.     -Tubulin showed equal loading and transfer. Representative immunoblots 
of epidermis from two OTCs are shown. Data are mean   ±   SD,   n   = 3.     JCB • VOLUME 184 • NUMBER 6 • 2009  820
  Increased expression of mitogenic factors 
by F    PPAR    /         results from attenuated IL-1    /
TAK1/AP-1 activation 
  Next, we sought to identify the signaling cascade that culmi-
nates in the up-regulation of the mitogenic growth factors in 
F    PPAR   /      . The expression of most of these genes is known to be 
regulated by the transcription factor activation protein-1 (AP-1; 
  Szabowski et al., 2000  ;   Florin et al., 2004  ). Although direct reg-
ulation of eotaxin-2 by AP-1 has not been reported, the expres-
sion of this gene is stimulated by IL-1 (  Watanabe et al., 2002  ; 
  Heiman et al., 2005  ). The increased expression of I-309 is likely 
the consequence of increased IL-8 level (  Wiener et al., 2008  ). 
We fi rst addressed the hypothesis that AP-1 belongs to the pathway 
through which PPAR   /    regulates the expression of mitogenic 
factors in F    PPAR   /      . We examined the levels of phosphorylated 
(activated) c-Jun in F    PPAR   /       and  F   CTRL     fi broblasts extracted from 
K    CTRL   /F   PPAR   /       and  K   CTRL   /F   CTRL     OTCs, respectively. Immunoblot 
analysis showed that F    PPAR   /       isolated from the K    CTRL   /F   PPAR   /      
OTCs had enhanced phosphorylated c-Jun, which is consistent 
with an increased activity of the AP-1 complex (  Fig. 2 B  ) and 
increased production of growth factors. 
  The TGF-activated kinase 1 (TAK1) plays a pivotal role in 
the activation of many genes, including genes encoding mito-
genic factors, via activation of AP-1 (  Florin et al., 2004  ,   2005  ). 
The IL-1   /    released by keratinocytes and TNF-     present in 
wound sites activate TAK1 (  Shim et al., 2005  ). To investigate the 
effect of PPAR   /    on TAK1 activation, we examined the expres-
sion of phosphorylated TAK1 in F    CTRL     and  F   PPAR   /       after  IL-1   
and TNF-     stimulations. F    CTRL     and F    PPAR   /       were treated with 
either vehicle (DMSO) or PPAR   /    agonist (GW501516) for 24 h 
prior to stimulation by either IL-1     or  TNF-  .  As  expected, 
there was an increase in phospho-TAK1 in vehicle-treated F    CTRL    
exposed to either IL-1     or  TNF-    (  Fig. 2 C  ). Cotreatment of 
these fi  broblasts with IL-1     and GW501516 signifi  cantly pre-
vented the increase in phospho-TAK1 levels in a dose-dependent 
manner (  Fig. 2 C   and   Fig. S2 A  ). In the F    PPAR   /      , a more robust 
increase in phospho-TAK1 was observed, which was only mar-
ginally affected by GW501516, showing that the ligand effect in 
F    CTRL     was PPAR   /    specifi  c (  Fig. 2 C   and Fig. S2 A). In con-
trast, neither ligand-activated PPAR   /    nor  PPAR  /    defi  ciency 
had an effect on TNF-   – mediated TAK1 activation ( Fig. 2 C  and 
Fig. S2 A). To further this observation, we performed chromatin 
immunoprecipitation (ChIP) using phospho  –  c-Jun antibodies on 
the keratinocyte growth factor (KGF) and granulocyte macro-
phage colony-stimulating factor (GMCSF) gene promoters in 
 fi broblasts from K    CTRL   /F   CTRL     and K    CTRL   /F   PPAR   /       OTCs (Fig. S2 B). 
There was more phospho  –  c-Jun immunoprecipitated chromatin 
from F    PPAR   /       when compared with F    CTRL    , pointing to enhanced 
AP-1 binding and activation of the KGF and GMCSF genes in 
F    PPAR   /      (Fig. S2 B). Together, these results indicate that PPAR  /   
specifi   cally attenuates IL-1    – mediated  TAK1  activation  and 
thus AP-1 activity. 
  Neutralization of IL-1    /     signaling abolishes 
the mitogenic action of F    PPAR    /         
  Our results showed that IL-1    – mediated  but  not  TNF-   – mediated 
TAK1 activation and AP-1  –  dependent expression of mitogenic 
on cocultured keratinocytes, providing evidence for an impor-
tant noncell autonomous PPAR   /   -dependent mechanism regu-
lating keratinocyte proliferation. 
  Organotypic cultures with F    PPAR    /         show 
increased expression of mitogenic factors 
  The paracrine effect of F    PPAR   /       on epidermal proliferation is 
likely mediated by changes in the secretion of mitogenic or 
antimitogenic factors by the fi  broblasts. To understand the 
mechanism underlying the enhanced epidermal proliferation 
in OTC with F   PPAR   /     , an unbiased protein array was performed. 
Infl  ammatory cytokine and growth factor arrays were used to 
compare conditioned media from OTCs reconstructed using 
WT keratinocytes with either F    CTRL     or  F   PPAR   /      . A total of 76 
distinct proteins were screened, and the results showed that 
the protein expression of several mitogenic factors and cyto-
kines were increased in OTC with F    PPAR   /       (  Table I  ). Notably, 
most of the proteins whose expression was increased have 
a known mitogenic action on keratinocytes. The expression 
of TGF-  1, which exerts an antiproliferative effect on keratino-
cytes, and the abundant IL-1    , constitutively produced by 
keratinocytes, remained unchanged. The expression of two 
proangiogenic factors, namely VEGF and placental growth 
factor (PIGF), were reduced in OTC with F    PPAR   /       when com-
pared with F    CTRL   . 
  To verify that a reduced PPAR   /    expression leads to a 
transcriptional up-regulation of mitogenic factor expression, we 
performed qPCR on selected mitogenic genes from OTC F    CTRL    
and F    PPAR   /       in the absence or presence of the PPAR   /    agonist 
GW501516. Consistent with the protein array results, F    CTRL    
exposed to GW501516 for 12 h showed a decrease in the 
  expression of these genes (  Fig. 2 A  ). Importantly, F    PPAR   /       ex-
pressed higher basal levels of these mitogenic factors and, as 
expected, ligand treatment had no effect. Altogether, fi  broblasts 
defi  cient in PPAR  /   have an increased expression of mitogenic 
factors (  Fig. 2 A  ). 
  Table I.       Relative fold change of protein expression in OTCs with 
F    PPAR    /        compared with F    CTRL       
Cytokines/growth factors Fold increase   
a   
KGF   
b   4.01    ±   0.11   
c   
IL-6   
b   5.56    ±   0.02   
c   
IL-8   
b   2.94    ±   0.14   
d   
IL-10 2.13   ±   0.07   
c   
IL-16 2.86   ±   0.11   
d   
GMCSF   
b   5.26    ±   0.10   
c   
I-309 3.33   ±   0.16   
c   
Eotaxin-2 3.03   ±   0.12   
c   
VEGF 0.25   ±   0.011   
d   
PIGF 0.33   ±   0.014   
d   
 
a  The intensities of signals were quantiﬁ  ed by densitometry. Positive control in-
cluded in the array blot was used to normalize and compare the results from 
different membranes. Values obtained from the control K    CTRL    /F    CTRL     OTC were 
arbitrarily assigned a value of 1. Values represent the mean fold increase as 
compared with control OTC (  n   = 3).
 
b  mRNA expression levels of these genes were further veriﬁ  ed by qPCR.
 
c  P   <   0.01.
 
d  P   <   0.1.821 PARACRINE ACTION OF PPAR    /     IN EPIDERMIS   • Chong et al. 
  Figure 2.       Reduced ﬁ  broblast PPAR    /     expression increases IL-1     activation of TAK1 and up-regulation of AP-1  –  controlled mitogenic target genes.   
(A) Expression of mitogenic factor mRNAs in 2-wk old OTC F    PPAR    /        and F    CTRL     treated with PPAR    /     agonist (500 nM GW501516 for 24 h) or vehicle. The ex-
pression levels of the indicated mitogenic factors were analyzed by qPCR and normalized to control ribosomal protein P0. Results are represented in fold in-
duction as compared with OTC F    CTRL    . (B) Immunoblot analysis of phosphorylated c-Jun from F    PPAR    /        and F    CTRL     extracted from K    CTRL    /F    PPAR    /        and K    CTRL    /F    CTRL     OTCs 
(  n   = 2), respectively. Total c-Jun and TAK1 protein expression level, which remains unchanged, showed equal loading and transfer. (C) Immunoblot analysis 
of IL-1     and TNF-     activation of TAK1 in F    CTRL     or F    PPAR    /       . Cells were treated with either vehicle (DMSO) or 800 nM GW501516 for 24 h prior to exposure to 
10 ng/ml IL-1     (top) or TNF-     (bottom). At the indicated time points, total cell lysates were extracted. Equal amounts of total protein (50   μ  g) were resolved, 
electrotransferred, and probed for phosphorylated TAK1 (Thr184/187), total TAK1, and     -tubulin. Values below each band represent the mean fold differ-
ences (  n   = 3) in expression level with respect to vehicle-treated F    CTRL     at 5 min, which was assigned the value of one. Data are mean   ±   SEM,   n   = 3.     JCB • VOLUME 184 • NUMBER 6 • 2009  822
factors were increased in F    PPAR   /      . This result suggested that the 
IL-1   /    pathway is responsible for the mitogenic effect of 
PPAR   /    knockdown in fi  broblasts. Conceivably, negating the 
effect of IL-1   /    with neutralizing antibodies against IL-1   /   
would counteract the effect of PPAR   /    knockdown in F    PPAR   /     . 
As anticipated, OTCs exposed to anti  –  IL-1   /    antibodies  dis-
played a reduction in Ki67-positive keratinocytes, and the mito-
genic action of F    PPAR   /       was completely abolished (  Fig. S3  , 
compare A with C), indicating that IL-1   /    signaling is a major 
pathway in the control of keratinocyte proliferation. This was 
further confi  rmed by immunoblot analysis of cyclin D1 and 
PCNA  ( Fig.  3 ,  compare   A   with   C ).  Similarly,  inhibiting  the  ac-
tion of the mitogenic factors should replicate the neutralizing 
effect of anti  –  IL-1   /    antibodies. To test this possibility, we 
treated the OTCs with neutralizing antibodies against KGF, 
GMCSF, and IL-6, which are the three most abundant mito-
genic factors in our model. To avoid possible compensatory 
  effects, we neutralized all three growth factors simultaneously. 
Consistent with the aforementioned results, all OTCs showed 
thinner epidermis and reduced keratinocyte proliferation when 
compared with the corresponding OTC treated with preimmune 
IgG (  Fig. 3, B and C   and Fig. S3, B and C). Altogether, our ob-
servations indicated that the mitogenic action of the F    PPAR   /       was 
caused by an increase in IL-1   /   – mediated  expression  of  mito-
genic factors via TAK1 and AP-1. 
  Human sIL-1ra gene is a direct target 
of PPAR    /     in ﬁ  broblasts 
  In vivo, the release of IL-1   /    by basal keratinocytes is suf-
fi  cient to maintain tissue homeostasis and to initiate cutane-
ous infl  ammation (  Groves et al., 1996  ;   Maas-Szabowski et al., 
2000  ). Although we did not detect a change in the expression 
of IL-1   /    in the protein array (  Table I  ), we clearly showed 
that PPAR   /    specifi  cally attenuated IL-1     response,  including 
the activation of TAK1. This suggested that the attenuation of 
IL-1     signaling by PPAR   /    occurs upstream of TAK1 activa-
tion. To examine whether PPAR   /    has a regulatory effect in 
IL-1   /    signaling cascade, we measured the mRNA levels of 
IL-1   ,  IL-1   , IL-1R1, IL-1R2, icIL-1ra, sIL-1ra, and IL-1R  –
  associated kinase, which are all key players of IL-1 signaling, in 
OTC epidermal keratinocytes (K    CTRL     and  K   PPAR   /     )  and  dermal 
fi  broblasts (F    CRTL     and F    PPAR   /      ). With the exception of a higher 
level of sIL-1ra in the OTC F    CRTL    , we detected no change in the 
expression of the other mediators of IL-1   /    signaling (  Fig. 4 A   
and not depicted). Consistently, elevated sIL-1ra was detected 
in the medium of OTC with F    CTRL     as compared with F    PPAR   /     , 
but no difference was observed in icIL-1ra protein within the 
fi  broblasts (  Fig. 4 A  ). 
  To determine whether the sIL-1ra promoter is directly 
regulated by PPAR   /    in the fi  broblasts, a 4.4-kb fragment 
  Figure 3.       Neutralizing antibodies against IL-1    /     or KGF, GMCSF, and 
IL-6 abolished the mitogenic effect of F    PPAR    /       .   (A  –  C) Immunoblot analysis 
of epidermis from indicated OTCs treated with 400 ng/ml IL-1    /     (A), 
KGF, GMCSF, and IL-6 (B) neutralizing antibodies (each at 400 ng/ml) 
or 400 ng/ml preimmune IgG (C). Antibodies were added to OTC 
medium at each change of medium. Cell proliferation was measured 
using cyclin D1 and PCNA. Values below each band represent the mean 
fold differences in expression level with respect to K    CTRL     from K    CTRL    /F    CTRL     
OTC, which was assigned the value of 1.     -Tubulin served as a load-
ing control. Representative immunoblots of epidermis from two indicated 
OTCs are shown.     
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  Figure 4.       Human sIL-1ra is encoded in a direct PPAR    /     target gene in ﬁ  broblasts.   (A) Expression of sIL-1ra and icIL-1ra mRNA (left) and protein (right) in 
OTC keratinocytes (K    CTRL     and K    PPAR    /       ) and ﬁ  broblasts (F    CRTL     and F    PPAR    /       ). sIL-1ra and icIL-1ra mRNA were analyzed by qPCR and normalized to ribosomal 
protein P0. The sIL-1ra level was determined by ELISA from medium of K    CTRL    /F    CTRL     and K    CTRL    /F    PPAR    /        OTCs. The icIL-1ra levels were measured by ELISA from 
cell lysates. (B) PPRE1 and PPRE3 of the human sIL-1ra gene are functional. Transactivation assay in ﬁ  broblasts cotransfected with a luciferase (luc) promoter 
driven by the human sIL-1ra promoter and pEF1  –      -galactosidase as control of transfection efﬁ  ciency. Relative positions of the three putative PPREs (PPRE 
1  –  3) and their mutants (mPPRE 1  –  3) are represented in closed and open ovals, respectively. Cells were treated with either 500 nM GW501516 (GW) 
and/or 10 ng/ml IL-1     for 24 h. Luciferase activity was measured, and normalized reporter activity is shown as fold induction as compared with untreated 
ﬁ  broblasts. (C) EMSA of human sIL-1ra PPRE1 and PPRE3. Radiolabeled PPRE1 (left) and PPRE3 (middle) were incubated either with RXR    , PPAR    /    , or 
both. NSC denotes nonspeciﬁ  c competitor, the nonfunctional MEd DR1 element in the malic enzyme promoter. SC denotes nonradiolabeled consensus PPRE 
(conPPRE). As positive control, conPPRE was used. Mutated consensus PPRE is denoted by mconPPRE. PPAR    /     did not bind to PPRE2 and mutated PPRE 
probes (mconPPRE, mPPRE1, mPPRE2, and mPPRE3; right). (D) PPAR    /     binds to PPRE1 and PPRE3 of the human sIL-1ra gene in ﬁ  broblasts. ChIP assays 
were conducted using preimmune IgG or antibodies against PPAR    /     (AB) in F    CTRL     (WT) and F    PPAR    /        (kd) ﬁ  broblasts extracted from two independent OTCs 
(OTC1 and OTC2). The regions spanning PPRE1 and PPRE2 of the sIL-1ra gene were ampliﬁ  ed using appropriate primers (  Table S1  ). A control region 
between PPRE1 and PPRE2 served as negative control. *, P   <   0.05; **, P   <   0.01. Data are mean   ±   SEM,   n   = 4.     JCB • VOLUME 184 • NUMBER 6 • 2009  824
of the promoter region was subcloned into a luciferase re-
porter vector and analyzed in transactivation assays. Three puta-
tive PPRE sequences were identifi  ed in the sIL-1ra promoter 
(GenBank no.   X64532  ), PPRE1 at position    1,038/  1,050, 
PPRE2 at    1,072/   1,084, and PPRE3 at    4,067/  4,079, 
using NUBIScan (  Fig. S4 A  ;   Podvinec et al., 2002  ). Transfected 
  Figure 5.       Reduced sIL-1ra in ﬁ  broblasts potentiates epidermal keratinocyte proliferation.   (A) Immunoblot analysis of epidermis from indicated OTCs 
treated with either vehicle (PBS) or 50 ng/ml exogenous IL-1ra. Cell proliferation was measured using PCNA and cyclin D1. Values below each band were 
derived as described in   Fig. 3 C  . (B) Speciﬁ  c knockdown of sIL-1ra in human ﬁ  broblasts. (left) Knockdown efﬁ  ciency was monitored by qPCR and normal-
ized with control ribosomal protein P0. Speciﬁ  city of knockdown was assessed by the relative expression level of icIL-1ra. (right) Protein expression of sIL-1ra 
and icIL-1ra as determined by ELISA. (C) Reduced ﬁ  broblasts sIL-1ra increase epidermal proliferation. OTCs were constructed using K    CTRL     with either control 
(F    CTRL    ) or sIL-1ra knockdown (F    sIL-1ra    ) ﬁ  broblasts. H  &  E, hematoxylin and eosin staining. (top) Ki67, cell proliferation (white arrows); DAPI, nuclear staining. 
Bars, 40   μ  m. (bottom) Bars, 20   μ  m. (left) Mean numbers of proliferating cells were derived as described in   Fig. S1  . Broken lines denote epidermal–dermal 
junction. (right) Immunoblot analysis of keratinocytes and ﬁ  broblasts extracted from two independent indicated OTCs. Equal amounts of total protein (50   μ  g) 
were resolved, electrotransferred, and probed for the indicated proteins. Values below each band represent the mean fold differences in expression level 
with respect to K    CTRL     or F    CTRL     extracted from K    CTRL    /F    CTRL     OTC. **, P   <   0.01; ***, P   <   0.001. Data are mean   ±   SD,   n   = 3.     825 PARACRINE ACTION OF PPAR    /     IN EPIDERMIS   • Chong et al. 
designed to target sIL-1ra was introduced into the human primary 
fi  broblasts. qPCR and ELISA analyses revealed   >  95% reduc-
tion in sIL-1ra mRNA and protein in the transduced fi  broblasts 
(  Fig. 5 B  ). The knockdown showed high specifi  city for the 
targeted sIL-1ra mRNA as the level of icIL-1ra mRNA was 
unchanged (  Fig. 5 B  , left). The sIL-1ra knockdown fi  broblasts 
(F    sIL-1ra    ) were used in OTC. Consistent with the aforementioned 
results, reducing the sIL-1ra production in fi  broblasts resulted 
in increased keratinocyte proliferation as indicated by the large 
increase in Ki67-positive cells and cyclin D1 and PCNA expres-
sion (  Fig. 5 C  , left and middle). This marked increase in epider-
mal cell proliferation is accompanied by enhanced activation 
of TAK1 and c-Jun in the F    sIL-1ra     when compared with F    CTRL    
(  Fig. 5 C  , right). 
  To provide further evidence that reduced sIL-1ra in fi  bro-
blasts results in the increased expression of mitogenic factors, 
protein arrays were used to compare conditioned media from 
OTCs using WT keratinocytes with either F   CTRL    or F   sIL-1ra    ( Table II ). 
In addition to those listed in   Table I  , the expression of two addi-
tional factors, chemokine ligand 1 (CXCL1)/growth-related on-
cogene-     and stromal-derived growth factor-1 (SDF-1), were 
increased in OTC F    sIL-1ra     compared with F    CTRL   .  The  expression 
of CXCL1 and SDF-1 is c-Jun dependent, and their expression 
increased keratinocyte proliferation (  Steude et al., 2002  ;   Florin 
et al., 2005  ). Similarly, when comparing OTCs with F    CTRL     and 
F    PPAR   /      , there was a trend for higher CXCL1 and SDF-1 expres-
sion in OTCs F    PPAR   /      , although the fold increase was not signifi  -
cant (unpublished data). 
  Finally, we also performed ChIP using phospho  –  c-Jun 
  antibodies on the KGF, GMCSF, and IL-6 gene promoters in 
 fi broblasts extracted from K    CTRL   /F   CTRL     and K    CTRL   /F   sIL-1ra     OTCs. 
The sequences spanning the AP-1  –  binding site were signifi  -
cantly enriched in the immunoprecipitates obtained from F    sIL-1ra    
primary fi  broblasts treated with the PPAR   /    ligand  GW501516 
alone showed only a modest approximately threefold increase in 
reporter activity (  Fig. 4 B  ). As expected, treatment with IL-1    
increased the reporter activity by     20-fold, which is consistent 
with an earlier study ( Smith et al., 1994 ). Importantly, this IL-1   –
  mediated transactivation was further enhanced by treatment 
with GW501516 (to     50-fold;   Fig. 4 B  ). To identify the func-
tional PPREs responsible for the PPAR-mediated up-regulation, 
site-directed mutagenesis of the PPREs was performed. Trans-
activation assays with the various mutated promoters clearly 
showed that the stimulatory effects of PPAR   /    were  mediated 
by two PPREs, i.e., PPRE1 and PPRE3. To investigate whether 
PPAR   /    was truly bound to these identifi  ed PPREs, electro-
phoretic mobility shift assay (EMSA) and ChIP were performed. 
As expected, specifi  c protein  –  DNA complexes were detected in 
EMSA for PPRE1 and PPRE3, which were effectively competed 
by a consensus PPRE oligonucleotide (  Fig. 4 C  ). As a positive 
control, the consensus PPRE oligonucleotide was used as a 
probe, which was specifi  cally competed by the unlabeled con-
sensus PPRE but not by a nonspecifi  c competitor containing a 
nonfunctional MEd (malic enzyme distal PPRE) DR1 element 
from the malic enzyme promoter (Fig. S4 B;   IJpenberg et al., 
2004  ). Similarly, ChIP performed on OTC F    CTRL     using a mono-
clonal anti-PPAR   /    antibody showed the binding of PPAR   /   
to both PPRE1 and PPRE3 (  Fig. 4 D  ). This effect was not ob-
served in F    PPAR   /      , and no signal was seen with preimmune serum 
either. In addition, no binding was detected to a control sequence 
residing between PPRE1 and PPRE3. These data clearly showed 
that PPAR   /    specifi   cally binds to the identifi  ed  functional 
PPREs in the human sIL-1ra promoter in OTC F    CTRL   .  They  in-
dicated that the human sIL-1ra promoter is a direct PPAR   /   
target in primary human dermal fi  broblasts. 
  Altogether, we showed that IL-1   /    secreted by the 
keratinocytes activates TAK1/AP-1 signaling, which up-regulates 
the expression of mitogenic factors in the fi  broblasts and thus 
enhances epidermal proliferation. We also showed that PPAR   /    
in the fi  broblasts plays a homeostatic role in which it stimu-
lates the expression of the sIL-1ra, modulates IL-1   /   – mediated 
mitogenic factors gene expression, and thus attenuates epider-
mal proliferation. 
  sIL-1ra knockdown ﬁ  broblasts increase 
keratinocyte proliferation 
  We showed that the sIL-1ra gene in fi  broblasts is a direct target 
of PPAR   /    and that accordingly, PPAR   /    knockdown results 
in a reduced production of sIL-1ra. To test whether the reduced 
production of sIL-1ra by F    PPAR   /       triggers keratinocyte prolifera-
tion, we examined the effect of exogenous IL-1ra supplemented 
into the medium of OTCs with F    PPAR   /     .  Importantly,  exogenous 
IL-1ra abolished the mitogenic effect of F    PPAR   /       (  Fig. S5 A  ). 
This was further confi  rmed by immunoblot analysis of cyclin D1 
and PCNA on the epidermis from the various OTCs (  Fig. 5 A  ). 
Thus, inhibition of IL-1   /    signaling using IL-1ra can rescue 
the pro-proliferating effect that PPAR   /    defi  ciency in the fi  bro-
blasts has on keratinocyte proliferation. 
  To strengthen these results, we examined the role of sIL-1ra 
on epidermal proliferation using RNA interference. An siRNA 
  Table II.       Relative fold change of protein expression in OTCs with 
F    sIL1ra     compared with F    CTRL       
Cytokines/growth factors Fold increase   
a   
KGF   
b   5.47    ±   0.22   
c   
IL-6   
b   6.11    ±   0.31   
c   
IL-8 3.47   ±   0.06   
c   
IL-10 3.88   ±   0.15   
c   
IL-16 3.78   ±   0.41   
c   
GMCSF   
b   7.74    ±   0.31   
c   
CXCL1/GRO-   2.67    ±   0.16   
d   
SDF-1 2.33   ±   0.07   
d   
I-309 4.57   ±   0.20   
c   
Eotaxin-2 6.19   ±   0.62   
c   
VEGF 0.22   ±   0.030   
d   
PIGF 0.25   ±   0.021   
d   
GRO-    , growth-related oncogene-    .
 
a  The intensities of signals were quantiﬁ  ed by densitometry. Positive control in-
cluded in the array blot was used to normalize and compare the results from 
different membranes. Values obtained from the control K    CTRL    /F    CTRL     OTC were 
arbitrarily assigned a value of 1. Values represent the mean fold increase as 
compared with control OTC (  n   = 3).
 
b  ChIP was performed on these genes using phospho  –  c-Jun antibody.
 
c  P   <   0.01.
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compared with F    CTRL     (  Fig. 6  , left). This was further confi  rmed 
by qPCR normalized to chromatin before immunoprecipitation, 
i.e., input (  Fig. 6  , right). Altogether, we concluded that reduced 
sIL-1ra production in the fi  broblasts, as observed in F    PPAR   /     , 
had a pronounced mitogenic effect on the epidermis. 
  PPAR    /    -KO mice show reduced sIL-1ra 
expression during early wound healing 
  Next, we evaluated the relevance of our fi  ndings during mouse 
skin wound healing, an in vivo model that involves the IL-1   /   
pathway. We fi  rst showed that activated PPAR   /    increased the 
IL-1      –  induced sIL-1ra expression in WT but not in KO primary 
fi  broblasts (  Fig. 7, A and B  ). Next, we examined the expression 
of IL-1ra in skin wound biopsies collected during early wound 
healing. qPCR analysis of early wound biopsies (days 1  –  3) 
showed a signifi  cantly lower sIL-1ra expression in KO tissue 
when compared with WT (  Fig. 7 C  ), which is consistent with 
the enhanced cell proliferation previously reported during early 
wound healing (  Tan et al., 2001  ). Notably, this difference in 
sIL-1ra expression was no longer detected in later wound biopsy 
specimens (  Fig. 7 C  , day 7). The analysis of wound fl  uids col-
lected from day 2 and 3 wound beds showed reduced sIL-1ra 
protein in KO mice when compared with WT mice (  Fig. 7 C  ). 
The expression of icIL-1ra was unchanged between WT and 
KO mice (unpublished data). Because keratinocytes only pro-
duced icIL-1ra, the change in sIL-1ra expression was attributed 
to the fi  broblasts, a hypothesis that was verifi  ed by qPCR analy-
sis of laser microdissected epithelium and dermis sections from 
day 4 wound biopsies of WT and KO mice (Fig. S5 B). Consis-
tent with our aforementioned results, wound KO dermis had 
  reduced sIL-1ra expression and concomitantly increased levels 
of IL-6, GMCSF, and KGF when compared with wound WT 
  Figure 6.       Increased c-Jun binding to AP-1 site of human KGF, GMCSF, and IL-6 gene promoter in F    sIL-1ra    .   ChIP of AP-1  –  binding site of human KGF 
(top), GMCSF (middle), and IL-6 (bottom) genes using phospho  –  c-Jun antibodies. The gene sequence spanning the AP-1 site and a random con-
trol sequence were analyzed by PCR in the immunoprecipitated chromatin of F    CTRL     and F    sIL-1ra     ﬁ  broblasts extracted from K/F    CTRL     and K/F    sIL-1ra     OTC, 
respectively. Preimmune serum was used as a control. qPCR was performed on immunoprecipitates of phospho  –  c-Jun antibodies and normalized 
to input (chromatin before immunoprecipitation). Results are represented in fold change as compared with F    CTRL     extracted from K/F    CTRL     OTC. M, 100 bp 
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expression in KO wounds ( Fig. 7 E ). In summary, in vivo wound 
biopsy and fl  uid analyses revealed lower sIL-1ra mRNA and 
protein in the KO mice. Our results showed that PPAR  /  -defi  cient 
fi  broblasts had reduced sIL-1ra expression compared with WT 
cells and that this reduced sIL-1ra production increased epider-
mal proliferation. 
dermis (  Fig. 7 D  ). These results confi  rmed that the expression 
of sIL-1ra was also modulated by PPAR   /    in mouse fi  broblasts. 
We next examined the effect of topical application of exogenous 
IL-1ra on the expression of IL-6, GMCSF, and mouse chemokine 
ligand 1 (KC; also known as CXCL1) in early wound biopsies. 
As expected, exogenous IL-1ra reduced IL-6, GMCSF, and KC 
  Figure 7.       Regulation of IL-1     signaling via 
PPAR    /     during wound repair in KO mice.   (A and 
B) Expression level of sIL-1ra (A) and icIL-1ra (B) in 
WT and KO ﬁ  broblasts. WT and KO primary ﬁ  bro-
blasts were treated with PPAR    /     ligand (100 nM 
GW501516 [GW]) and/or 10 ng/ml IL-1    . The 
mRNA (left) and protein (right) expression levels 
were measured by qPCR and ELISA, respectively. 
(C) Expression level of sIL-1ra in early wound bi-
opsies of KO mice. Wound ﬂ   uids and biopsies 
were collected at the indicated day post-wounding 
(days 1  –  3,   n   = 7; day 7,   n   = 4). Unwounded skin 
was used as control (ctrl;   n   = 4). sIL-1ra mRNA 
and protein levels were determined by qPCR and 
ELISA, respectively. (D) Expression of sIL-1ra, icIL-
1ra, KGF, IL-6, and GMCSF mRNAs from laser 
capture microdissected (LCM) dermis of WT (  n   = 3) 
and KO (  n   = 4) wound biopsies. Indicated mito-
genic factor mRNA levels were analyzed by qPCR 
and normalized to control ribosomal protein P0. 
(E) Expression levels of indicated factor mRNAs in 
vehicle (veh; carboxymethylcellulose)- and IL-1ra  –
  treated (3   ×   2.5   μ  g) wounds of KO and WT mice 
as compared with corresponding unwounded 
(control) skin. *, P   <   0.05; **, P   <   0.01; ***, P   <   
0.001. Data are mean   ±   SEM,   n   = 4.     JCB • VOLUME 184 • NUMBER 6 • 2009  828
fi  broblasts signifi  cantly infl  uence epithelial cell fate (  Cheng 
et al., 2005  ). In the presence of IL-1  –  producing keratinocytes, 
PPAR   /    was the predominant PPAR isotype in fi  broblasts. 
 Interestingly,  PPAR  /    directly increased the expression of 
sIL-1ra in the fi  broblasts that acted in an autocrine manner to 
modulate the expression of several IL-1  –  dependent mitogenic 
factors (  Fig. 8  ). This autocrine action is possible because IL-1R1 
is the predominant IL-1R subtype in fi  broblasts, whereas kera-
tinocytes exhibit IL-1R2 that has very low affi  nity for sIL-1ra 
and protects them from an exacerbated autocrine action of the 
IL-1   /    that they constitutively produce. This study underscores 
the fact that PPAR   /    in the dermal fi  broblasts fulfi  ls a homeo-
static role during epidermal formation, balancing cell prolifera-
tion via a control on IL-1   /    signaling. 
  It was reported that the enhanced TPA-induced hyper-
plasia in KO mice was a result of reduced ubiquitin C, whose 
expression is regulated by PPAR   /    ( Kim  et  al.,  2004 ).  The  im-
paired ubiquitin-dependent proteosome-mediated protein turn-
over in KO mice resulted in a higher PKC     level, increased 
Raf1, and MAPK/extracellular signal-regulated kinase activ-
ities, which led to an increase in cell proliferation (  Kim et al., 
2005  ). Other studies have shown that PKC     overexpression  in 
two different models did not affect the proliferation of primary 
human keratinocytes and of PKC     transgenic mouse keratino-
cytes (  Wang and Smart, 1999  ;   Cataisson et al., 2003  ). In fact, 
PKC     transgenic mouse keratinocytes treated with TPA under-
went apoptosis (  Cataisson et al., 2003  ). This is in apparent 
  Discussion 
  Wound healing is a complex process that consists of a cascade 
of overlapping events, including infl  ammation reepithelializa-
tion and remodeling, directed at the restoration of the epider-
mal barrier. Throughout the whole healing process, interaction 
between different cell types provides coordination of the indi-
vidual events, allowing for a temporal and spatial control. 
Reepithelialization is accomplished by increased keratinocyte 
proliferation and guided migration over the granulation tissue. 
Such processes require ordered changes in keratinocyte be-
havior that is dictated by the interplay of keratinocytes with 
dermal fi  broblasts, i.e., epithelial  –  mesenchymal communica-
tion. The results presented in this study characterize a novel 
unsuspected role of PPAR   /    in  fi  broblasts, which ensure a 
balanced functional interaction between dermis and epidermis. 
We show that keratinocyte proliferation is controlled by the der-
mal fi  broblasts that produce AP-1  –  dependent mitogenic factors 
under the control of the IL-1/TAK1 signaling cascade whose 
activity level is modulated by PPAR   /    via a direct control 
sIL-1ra production (  Fig. 8  ). 
  Epidermal homeostasis requires a continuous exchange of 
signals with the underlying dermal compartment. Fibroblasts 
are a major cell type in the dermis, and their function in regulating 
extracellular matrix deposition and growth factor expression 
determines the differentiation states of the epidermis. Previous 
studies have showed that gene expression changes in the dermal 
  Figure 8.       The autonomous and nonauto-
nomous actions of PPAR    /    .   PPAR    /     confers 
antiapoptotic properties to keratinocytes and 
potentiates their migration via AKT1 and Rho 
GTPases in a cell-autonomous manner (  Di Poi 
et al., 2002  ;   Tan et al., 2007  ). PPAR    /     also 
inﬂ   uences keratinocyte differentiation in a 
yet unknown mechanism. PPAR    /     regulates 
epidermal proliferation in a nonautonomous 
fashion via a paracrine mechanism. IL-1 con-
stitutively produced by the adjacent keratino-
cytes activates c-Jun, an obligate partner of 
AP-1 transcription factor via TAK1, and con-
sequently increases the production of several 
mitogenic factors. The expression of PPAR    /     
in the underlying ﬁ  broblasts attenuates this IL-1 
signaling via the production of sIL-1ra. sIL-1ra 
has little afﬁ  nity for IL-1R2, which is highly 
expressed in keratinocytes. Thus, sIL-1ra acts 
in an autocrine fashion onto the ﬁ  broblasts, 
which expressed the predominant functional 
IL-1R1. The binding of sIL-1ra to IL-1R1 modu-
lates the IL-1  –  mediated signaling events and 
consequently decreases the production of 
several AP-1  –  mediated mitogenic factors. The 
mitogenic factors exert a reduced paracrine 
effect on the epithelial proliferation via their 
cognate receptors (R). Therefore, PPAR    /     in 
the ﬁ  broblasts plays an important homeostatic 
role in maintaining epidermal homeostasis, 
the absence of PPAR    /     resulting in signiﬁ  cant 
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in tumorigenesis remains debatable because there is evidence 
that this PPAR isotype potentiates or attenuates epithelial can-
cers (  Gupta et al., 2000  ;   Barak et al., 2002  ;   Harman et al., 
2004  ). Although this question is not directly addressed in this 
study, our preliminary data showed that F    PPAR   /       can increase 
the proliferation of human squamous carcinoma cells (unpub-
lished data). 
  Materials and methods 
  Reagents 
  The following antibodies and suppliers were used: anti-Ki67, antikeratin 
10, anti-involucrin, antikeratin 6 (Novacastra), anti-PPAR    , anti-PPAR    /    , 
and anti-PPAR     (Millipore and Thermo Fisher Scientiﬁ  c); all cytokines and 
neutralizing antibodies against IL-1    , IL-1    , KGF, IL-6, and GMCSF (Pepro-
Tech); anti  –  c-Jun, antiphospho(Ser63)  –  c-Jun, anti-TAK1, and antiphospho-
TAK1 (Cell Signaling Technology); and Alexa Fluor 488  –  conjugated goat 
anti  –  mouse antibody (Invitrogen). Real-time reagent SYBR GreenER (Invitro-
gen), rat tail collagen type I (BD), and transfection reagent Superfect 
(QIAGEN) were used. All restriction enzymes and DNA/RNA modifying 
enzymes were obtained from Fermentas. Double-promoter lentivirus-based 
siRNA vector and pFIV Packaging kit (System Biosciences) was used. The 
PPAR    ,     /    ,      Complete Transcription Factor Assay kit was obtained from 
Cayman Chemical. Primary neonatal human ﬁ  broblasts and keratinocytes 
were obtained from Invitrogen. GW501516 was obtained from Enzo Bio-
chem, Inc. Otherwise, chemicals were obtained from Sigma-Aldrich. 
  Total RNA isolation, reverse transcription PCR, and qPCR 
  Total RNA was extracted from fresh tissues using Aurum total RNA kit 
(Bio-Rad Laboratories) following the supplier  ’  s protocol. 5     g total RNA 
was reverse transcribed with oligo-dT primers using RevertAid H Minus 
M-MuLV (Fermentas). After reverse transcription, the RNAs were removed 
by RNase H digestion. qPCR was performed with platinum Taq poly-
merase and SYBR GreenER super mixes using a PCR machine (MiniOpti-
con; Bio-Rad Laboratories). Melt curve analysis was included to assure 
that only one PCR product was formed. Primers were designed to gener-
ate a PCR ampliﬁ  cation product of 100  –  250 bp. Only primer pairs yield-
ing unique ampliﬁ  cation products without primer dimer formation were 
subsequently used for real-time PCR assays. Expression was related to the 
control gene ribosomal protein P0 (RPLP0), which did not change under 
any of the experimental conditions studied. The sequence of primers is 
available in   Table S1  . For each wound biopsies, 10 8-  μ  m-thick tissues 
were microdissected and pooled. RNA was isolated from microdissected 
paraformaldehyde-ﬁ   xed parafﬁ   n-embedded sections using RecoverAll 
  Total Nucleic Acid Isolation kit (Applied Biosystems). 5 ng RNA was sub-
jected to Full Spectrum Complete Transcriptome RNA Ampliﬁ  cation kit 
(System Biosciences) prior to qPCR. 
  Lentivirus-mediated knockdown of PPAR    /     and sIL-1ra 
  Two siRNAs targeting the human PPAR    /    , one against sIL-1ra and one 
unrelated control siRNA, were subcloned into the lentiviral-based siRNA 
vector pFIV-H1/U6-puro. The correct pFIV siRNA constructs were veriﬁ  ed 
by sequencing using H1 primer. The sequence of the siRNAs was as 
given in Table S1. Transduction-ready pseudoviral particles (System Bio-
sciences) were produced and harvested as described by the manufac-
turer. Transduced cells were enriched by puromycin selection for 1 wk. 
Western blot analysis, ELISA, or qPCR were used to assess the efﬁ  ciency 
of knockdown. 
  Transactivation assay 
  An     4.4-kb (    1572 to     5980) promoter of the human sIL-1ra was PCR 
ampliﬁ  ed from human genomic DNA using Pfu polymerase. The primer 
pairs used are given in Table S1. The resulting fragment was used for a 
second PCR ampliﬁ  cation step introducing SacI and BglII sites that were 
used for subcloning into the pGL-3 Basic vector (Promega). Site-directed 
mutagenesis of the three putative PPREs (PPRE1 at     1038/    1050, PPRE2 
at     1072/    1084, and PPRE3 at     4067/    4079) were achieved using 
QuikChange site-directed mutagenesis kit (Agilent Technologies). Human 
ﬁ  broblasts were routinely grown in medium 106 (Invitrogen). Fibroblasts 
were cotransfected with a luciferase reporter driven by the various sIL-1ra 
promoter constructs and pEF1  –      -galactosidase as a control of transfection 
efﬁ  ciency using Superfect. After transfection  ,   cells were incubated in the 
discrepancy with the delayed wound healing kinetics observed 
in KO mice. Enhanced keratinocyte proliferation was also 
  observed in many situations not involving TPA exposure 
(  Michalik et al., 2001  ;   Tan et al., 2001  ). Furthermore, no differ-
ence was observed in phosphorylated MEK-1/2 and ERK-1/2 
expression between untreated KO and WT mice (  Kim et al., 
2005  ). This raises the question of how epidermal hyperprolif-
eration occurs at wound edges early after injury of KO mice 
(  Michalik et al., 2001  ). These observations point to a complex 
role of PPAR   /    in cell proliferation. Our results showing that 
PPAR   /    defi  ciency in fi  broblasts increases their mitogenic ef-
fect on epithelial cells unveil part of this complexity. The under-
lying mechanism involves reduced sIL-1ra production by the 
fi  broblasts, allowing a stronger IL-1 signaling, resulting in in-
creased TAK1 activity with a consequent rise in mitogenic 
growth factor production. The in vivo relevance of this mecha-
nism was observed during early wound repair in KO mice with 
reduced sIL-1ra in early but not late wound biopsies. This pat-
tern is consistent with the early epidermal hyperproliferation 
reported in KO mice during the infl  ammatory phase of wound 
healing (  Tan et al., 2001  ). 
  This study and earlier studies suggest different roles of 
PPAR   /   in the dermis and adjacent epidermis ( Tan et al., 2001 ; 
  Man et al., 2008  ). The activation of PPAR   /    conferred  anti-
apoptotic properties to keratinocytes, which are mediated in part 
by the increased activation of the PKB     pathway (  Di Poi et al., 
2002  ). This antiapoptotic role was similarly observed in mouse 
tubular renal epithelial cells (  Letavernier et al., 2005  ) and in 
human keratinocyte HaCaT cells (  Schug et al., 2007  ). Our data 
now clearly show that PPAR   /    signaling in fi  broblasts has a 
pronounced effect on the growth potential of adjacent epithelia. 
Such differential roles were previously observed for TGF-   1 
signaling in wound repair (  Beanes et al., 2003  ). Interestingly, an 
in vivo cross talk between TGF-    1/Smad3 and PPAR   /    sig-
naling in keratinocytes during wound repair has been reported 
(  Tan et al., 2004  ). The development of a vascular supply is im-
portant for wound healing. Interestingly, we also observed a 
  reduced expression of VEGF and PIGF in OTC with F    PPAR   /     . 
Although it is tempting to speculate that both VEGF and PIGF 
may be target genes of PPAR   /   , their regulation are complex 
and context dependent, involving numerous factors such as 
pVHL (von Hippel-Lindau tumor suppressor), Sp-1, NF-   B 
(nuclear factor      light chain enhancer of activated B cells), hypoxia-
inducible factor     , and AP-1, among others (  Mukhopadhyay et al., 
1997  ;   Green et al., 2001  ). Importantly, epithelial  –  mesenchymal 
interactions can also modulate VEGF expression (  Ong et al., 
2007  ). During wound repair, an impaired angiogenesis is in line 
with the delayed wound healing observed in KO mice (  Michalik 
et al., 2001  ). 
  The tissue microenvironment plays a pivotal role in 
modulating gene expression and cellular behavior, including 
epithelial  –  mesenchymal communication. Likewise, the micro-
environment milieu is constituted by factors produced and re-
leased by these various cell types as communication signals. 
Of interest, the activation of IL-1 signaling was reported to 
coerce the growth of tumors, whereas its repression by IL-1ra has 
an antitumor effect (  Lewis et al., 2006  ). The role of PPAR   /   JCB • VOLUME 184 • NUMBER 6 • 2009  830
  Measurement of cytokines by ELISA 
  The concentration of sIL-1ra and icIL-1ra measured using sandwich ELISA 
(R  &  D Systems). In brief, 2   ×   10 
5   cells were cultured in a 35-mm culture dish 
with 750   μ  l of medium and subjected to the indicated treatments. After 24 h, 
the media were harvested and treated with the addition of Complete 
protease inhibitors (Roche). The level of sIL-1ra was measured in culture 
  supernatants accordingly to the manufacturer  ’  s instruction. To measure icIL-
1ra, the cells were washed thoroughly, harvested by treatment with trypsin, 
and collected by centrifugation in fresh serum-free culture medium. The cell 
pellet was resuspended in 750   μ  l of medium, disrupted by sonication, and 
the debris was removed by centrifugation. The concentration of icIL-ra in 
the supernatant was measured by ELISA. 
  Protein arrays 
  Human Inﬂ  ammation Antibody Array 3 and Growth Factor Antibody Array 
membranes (RayBiotech) were processed according to the manufacturer  ’  s 
protocol. Protein spots were detected by chemiluminescence. Signal inten-
sities were quantiﬁ  ed using ImageJ (National Institutes of Health) analysis 
software and were normalized with the mean intensity of the positive con-
trols on each membrane. 
  Western blot analysis 
  Epidermis was physically separated from OTC after a 20-min treatment 
with dispase. Fibroblasts embedded in collagen were isolated after colla-
genase treatment. For Western blotting, protein extracts were made in 
ice-cold lysis buffer (20 mM Na  2  H  2  PO  4  , 250 mM NaCl, 1% Triton X-100, 
and 0.1% SDS). Equal amounts of protein extracts (50   μ  g) were resolved 
by SDS-PAGE and electrotransferred onto PVDF membranes. Membranes 
were processed as described by the manufacturer of antibodies, and 
proteins were detected by chemiluminescence (Millipore). Coomassie 
blue  –  stained membrane or tubulin was used to check for equal loading 
and transfer. 
  Online supplemental material 
  Fig. S1 shows immunoﬂ   uorescence staining of 2-wk old OTCs. Fig. S2 
shows immunoblot analysis of IL-1     and TNF-     activation of TAK1 in F    CTRL     
or F    PPAR    /        ﬁ  broblasts and ChIP of AP-1  –  binding site of human KGF and 
GMCSF genes using phospho  –  c-Jun antibodies. Fig. S3 shows immunoﬂ  uor-
escence staining of 2-wk-old OTCs treated with neutralizing antibodies 
against IL-1     and      or against KGF, GMCSF, and IL-6. Fig. S4 shows the 
alignment of the two functional PPREs in human sIL-1ra promoter to consen-
sus PPRE. Fig. S5 shows immunoﬂ  uorescence staining of 2-wk old OTCs 
derived using PPAR    /    -deﬁ  cient ﬁ  broblasts (F    PPAR    /       ) treated with either 
vehicle or exogenous IL-1ra. Table S1 shows the sequence of primers used 
in this study. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200809028/DC1. 
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